Trial · NCT06545500
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) | Baseline (pre-dose for each treatment period) and Day 7 | Liters | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Average Baseline FEV1 to Average Peak FEV1 Measured Over 4 Hours | Baseline (pre-dose for each treatment period) and Day 7 | Liters | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h) | Baseline (pre-dose for each treatment period) and Day 7 | Liters | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h) | Baseline (pre-dose for each treatment period) and Day 7 | Liters | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Average Baseline FEV1 to Evening Trough FEV1 | Baseline (pre-dose for each treatment period) and Day 7 | Liters | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Average Baseline FEV1 to Peak FEV1 Measured Over 4 Hours After First Dose | Baseline (pre-dose) and Day 1 | Liters | LEAST_SQUARES_MEAN | |
| SECONDARY | Change From Average Baseline FEV1 to Average FEV1 AUC0-4h Measured After First Dose | Baseline (pre-dose) and Day 1 | Liters | LEAST_SQUARES_MEAN | |
| SECONDARY | Number of Treatment Emergent Adverse Events (TEAEs) | From first dose through the follow-up contact (approximately 8 weeks per participant). Overall safety data was collected for 5 months total. | Events | NUMBER | |
| SECONDARY | Glycopyrronium Free Base AUC0-12h | After morning dose Day 7 | Placebo was excluded from the PK concentration listings. | h*pg/mL | MEAN |
| SECONDARY | Glycopyrronium Free Base Maximum Plasma Drug Concentration (Cmax) | After morning dose Day 7 | Placebo was excluded from the PK concentration listings. | pg/mL | MEAN |
| SECONDARY | Glycopyrronium Free Base Time to Maximum Plasma Drug Concentration (Tmax) | After morning dose Day 7 | Placebo was excluded from the PK concentration listings. | hours | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06545500/outcomes